FUNDAMENTAL AND CLINICAL STUDIES ON PANIPENEM/BETAMIPRON
スポンサーリンク
概要
- 論文の詳細を見る
Fundamental and clinical studies were conducted using panipenem/betamipron (PAPM/BP) which is an injectable combined drug of newly developed carbapenem antibiotic, panipenem (PAPM) and N-benzoyl-β-alanine (betamipron (BP)) at a ratio of 1:1, and the results were obtained as follows.<BR>1) The MICs of PAPM and the control drugs such as imipenem (WM), piperacillin (PIPC), cefoperazone (CPZ) and ceftazidime (CAZ) against the clinical isolates were determined in accordance with the Standard Method established by Japan Society of Chemotherapy.<BR>The MIC<SUB>80</SUB>s of PAPM against <I>Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter</I> spp., <I>Serratia marcescens, Proteus mirabilis, Proteus vulgaris, Citrobacter freundii</I> and <I>Pseudomonas aeruginosa</I> were 0.10, 3.13, 0.20, 0.78, 0.78, 0.78, 3.13, 1.56, 0.39 and 50μg/ml, respectively, and the antibacterial activity of PAPM was as potent as that of IPM. In particular, the antibacterial activity of PAPM against Gram-positive cocci was far more potent than that of PIPC, CPZ and CAZ. The antibacterial activity of PAPM against <I>P. aeruginosa</I> was as potent as that of PIPC, CPZ and CAZ, but PAPM showed more potent antibacterial activity than the control drugs against most other Gram-negative bacilli except for <I>Proteus</I> spp.<BR>2) PAPM/BP was used in the treatment of 7 patients (3 patients with pneumonia, 1 with chronic bronchitis, 1 with sepsis and 2 with cystitis). Their age ranged from 30 years to 74 years and there were 2 males and 5 females. All of these patients had one or more underlying diseases which are prone to cause infectibility. PAPM/BP was given in the daily dosage of 1.0g/1.0g-2.0g/2.0g for 3-23 days, and the clinical response was excellent in 1 case, good in 5 and unknown in 1. The identified causative bacteria included <I>Haemophilus influenzae, Branhamella catarrhalis, P. aeruginosa, Xanthomonas maltophilia</I> and <I>K. pneumoniae</I> and most of these causative bacteria became negative. But in 2 cases, the causative bacteria were replaced. Neither side effect nor abnormal laboratory test value were observed.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.